Phaseline

Targets › HIF1A

HIF1A (Hypoxia-inducible factor 1-alpha): drug programs, companies and trials

2 programs from 2 companies in 5 trials: 2 Phase 3, 2 Phase 2, 1 Phase 1; Genitourinary, Hematology, Oncology; next expected readout Dec 2026.

Functions as a master transcriptional regulator of the adaptive response to hypoxia. Under hypoxic conditions, activates the transcription of over 40 genes, including erythropoietin, glucose transporters, glycolytic enzymes, vascular endothelial growth factor, HILPDA, and other genes whose protein products increase oxygen delivery or facilitate metabolic adaptation to hypoxia. (UniProt, Q16665)

Open in Phaseline: the race on HIF1A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Kind PharmaceuticalsAND017
HIF-1α stabilizer
HIF1APhase 3Anemia Due to Chronic Kidney Disease; Myelodysplastic Syndromes; β -ThalassemiaDec 2026
ImmunoGenesisEvofosfamide
Hypoxia-inducible factor 1-alpha (HIF-1α) inhibitor; prodrug activated under hypoxic condi
HIF1APhase 1Metastatic Prostate CancerOct 2027

Conditions

Anemia Due to Chronic Kidney Disease (2) Myelodysplastic Syndromes (1) β -Thalassemia (1) Metastatic Prostate Cancer (1)

Modalities

small molecule (1), mixed (1)

Companies

Kind Pharmaceuticals (1) ImmunoGenesis (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.